Metabolomics Market USD 1.24 Billion by 2020
Visit the Metabolomics Market 2013-2020 report at https://www.ihealthcareanalyst.com/report/metabolomics-market/
Metabolomics is the scientific study of chemical processes involving metabolites, whereas metabolome represents the collection of all metabolites in a biological cell, tissue, organ or organism, which are the end products of cellular processes. mRNA gene expression data and proteomic analyses reveal the set of gene products being produced in the cell, data that represents one aspect of cellular function including systems biology and functional genomics that integrates proteomic, transcriptomic, and metabolomic information to provide a better understanding of cellular biology.
The metabolomics market report estimates the market size (Revenue USD million - 2013 to 2020) and key market segments based on detection and separation techniques used, its applications (biomarker discovery, clinical toxicology, drug assessment, and nutrigenomics), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global metabolomics market including company overview, financial snapshot, key products, technologies and services offered, and recent trends in strategic management.
The global metabolomics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
1.1. Detection Techniques
1.2. Separation Techniques
2.1. Biomarker Discovery
2.2. Clinical Toxicology
2.3. Drug Assessment
3. Company Profiles
3.1. Agilent Technologies Inc.
3.2. Biocrates Life Sciences AG
3.3. Bio-Rad Laboratories, Inc.
3.4. Bruker Corporation
3.5. Human Metabolome Technologies Inc.
3.6. LECO Corporation
3.7. Metabolon Inc.
3.8. Shimadzu Corporation
3.9. ThermoFisher Scientific Inc.
3.10. Waters Corporation
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
Phone: (314) 736-9294.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metabolomics Market USD 1.24 Billion by 2020 here
News-ID: 377877 • Views: 669
More Releases from iHealthcareAnalyst, Inc.
Global Blood Gas Monitoring Products Market Growing at CAGR of 6.2% to Reach $5. …
The global market for blood gas monitoring products is estimated to reach $5.5 billion by the end of 2025, expanding at a CAGR of 6.2% during the forecast period, supported by growing geriatric population, rising prevalence of chronic diseases, and technological advances. The global blood gas monitoring devices market research report provides market size (Revenue US$ Million 2017 to 2025), market share analysis, growth trends and forecast (CAGR%, 2019 to 2025).
Advances in Mobile Connectivity Services to Drive Telemedicine Technologies and …
According to a new market research report Telemedicine Technologies and Services Market 2015-2023 published by iHealthcareAnalyst, Inc., the global computer-aided detection market to reach US$ 73.2 Billion by 2023, expanding at a CAGR of 13.5% from 2018-2023. Visit the Global Telemedicine Technologies and Services Market Analysis and Forecast 2018-2023 report at https://www.ihealthcareanalyst.com/report/telemedicine-technologies-services-market/ The global telemedicine technologies and services market newly published (updated 2018) report estimates the market size (US$ million 2015-2023)
Global Internet Pharmacies Market to Cross US$ 100 Billion by 2023
The global internet pharmacies market is estimated to reach US$ 106 Billion by 2023, growing at a CAGR of 15.7% over the forecast period, driven by rising personal disposable income, lower prices, surge in internet penetration, stupendous growth of online retail market and a large number of online players entering the online healthcare product segment. The major players are in a race to increase their share in the industry by
Global Cerebrospinal Fluid Management Market to Reach 1.9 US$ billion by 2023 gr …
According to a new market research report (updated 2018) published by iHealthcareAnalyst, Inc., Cerebrospinal Fluid Management Market – Global CSF Products Analysis and Forecast 2018-2023, the global cerebrospinal fluid management market was valued at US$ 1,045 Million in 2013 and to reach US$ 1.9 billion by 2023, growing at a CAGR of 5.5% from 2018-2023. Visit the Global Cerebrospinal Fluid Management Market – Global Patient Solutions, System Strengthening and End Users
More Releases for Ana
Antechamber Solo show Ana Mazzei
Ana Mazzei Antechamber 12 November 2018– 5 January 2019 In her first solo exhibition at Green Art Gallery, Ana Mazzei fully embraces the notion of theatricality and spectatorship, both very central to her practice, to present a group of new works specifically created for the space. Titled Antechamber, the show is staged as an intermediary space between the real world outside the gallery and an imaginary ‘other space’. Walking along this in-between space, viewers have to negotiate
Intravenous Solutions Market 2018-2025 Growth Factors Ana
This report studies the global Intravenous Solutions market, analyzes and researches the Intravenous Solutions development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Baxter Hospira B. Braun Melsungen Fresenius Kabi Claris Lifesciences Grifols Vifor Pharma JW Life Science Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Browse the full report
World's first 767-300 Boeing Converted Freighter goes to ANA
SINGAPORE, June 16, 2008 – Singapore Technologies Aerospace Ltd (ST Aerospace), Boeing [NYSE: BA] and All Nippon Airways (ANA) celebrated the completion and certification of the first 767-300 Boeing Converted Freighter (BCF) at a redelivery ceremony held in Singapore today. Boeing launched the 767-300BCF passenger-to-freighter conversion (PTF) programme in 2005 with three firm orders and four options from ANA. Since then, ANA has exercised all the options,
direct/ All Nippon Airways: ANA Interim results amendment
In line 5 of paragraph 1, Operating Profit is reported as having fallen to 696.1 billion yen. This is in fact the figure for Operating Costs. The correct figure for Operating Profit is 67.0 billion yen. Please accept our apologies for this mistake. The first chart on the first page, entitled Consolidated Financial Performance, gives the correct figures. The announcement distributed by Hugin directnews. The issuer is solely responsible for the
direct/ All Nippon Airways: ANA Interim FY07 Profitable
ANA Reports Profitable First Six Months to Fiscal Year 2007 - record revenue on strong international growth TOKYO October 31, 2007 ANA Group today reported a record consolidated net profit of 105.5 billion yen on record revenue of 763.2 billion yen for first six months of fiscal year 2007, ended September 30, a 217% and 1.4% increase respectively. Net profit was boosted considerably by the sale of ANA Group´s hotel assets on
direct/ All Nippon Airways: ANA Corporate Plan FY2007
Japan´s first all business Class Jet to Link Tokyo and Mumbai - TOKYO January 25, 2007 ANA today announced its corporate plan for the 2007 fiscal year, April 1, 2007 - March 31, 2008. Fiscal 2007 constitutes the second year of ANA´s Medium-Term Strategy FY2006-2009, the aim of which is to establish ANA as Asia´s No 1 airline for quality, customer satisfaction and value creation in line with the future